Can-Fite Biopharma Ltd
Research Can-Fite Biopharma Ltd (CANF) on Bullrun: market cap USD 3.82M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCANF
- ExchangeNYSE MKT
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.82M
- Financial periodFY2025
- RevenueUSD 405.00K
- Revenue growth-39.9%
- Net income-USD 9.83M
- Free cash flow-USD 8.95M
Valuation Snapshot
latest market cap is USD 3.82M.
About Can-Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer;
Frequently asked questions
What is Can-Fite Biopharma Ltd's market cap?
Can-Fite Biopharma Ltd's market capitalization is USD 3.82M.
What does Can-Fite Biopharma Ltd do?
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.